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Genetically modified mouse models have been extensively used to trace stem cell niches, evaluate stem cell identities, and provide translational insights into human stem cell biology. Currently, we still face considerable experimental discrepancies and data reproducibility issues related to the use of mouse genetic models, which have led to several major controversies in fundamental biological questions in the bone marrow (BM) stem cell field. For example, the precise locations of hematopoietic stem cell (HSC) niches, which are predominantly determined by the use of various mouse reporter genes, are currently under debate ([@bib1], [@bib3], [@bib29], [@bib43]). Moreover, "mesenchymal stem cells" are a vague and confusing concept, which was primarily based on "bone marrow stromal cells" ([@bib21], [@bib45]) and on multipotent skeletal stem cells (SSCs), without the use of definitive markers ([@bib6]). Furthermore, it is unclear whether local neural crest cells could directly contribute to SSCs in BM ([@bib23], [@bib40], [@bib53]). Thus, BM stem cells represent a more diffuse-and-complex biological area, having many unidentified variables that are responsible for existing experimental discrepancies and data irreproducibility ([@bib41]). Nonetheless, it appears that all the above controversies are, at least, associated with one common methodological basis; i.e., the differential use of mouse reporter strains.

During the past two decades, marker gene identifications combined with cell lineage tracing using reporter mouse strains have had a major impact on understanding the complexity of cellular dynamics and commitments of murine BM stem cell niches at various developmental stages. However, choices of marker genes, constructions of reporter murine strains, and even experimental designs have unavoidable bias, which have limited our understanding of BM stem cell biology (reviewed in [@bib6], [@bib26], [@bib37], [@bib42]). Current technologies used to identify BM stem cells mainly rely on various mouse reporter strains based on limited numbers of marker genes (e.g., nestin \[*Nes*\], leptin receptor \[*Lepr*\], *Cspg4*/*NG2*, and *Wnt-1*). Perplexingly, these marker genes usually have high levels of expression in non-BM tissues or organs, thus having limited specificity in BM. For instance, in mouse embryos, *Nes*, *Lepr*, *Cspg4*, and *Wnt-1* all have higher levels of expression in the brain than in the BM. At present, many unmanageable variables in mouse experiments stem from genetically engineered reporter genes in mouse strains. Therefore, optimizing murine models to resolve existing controversies and to translate the information from animal models into human BM biology has been challenging.

To accurately define diverse BM cell lineages and differentiation, in this review, we systematically untangle the complicated data interpretation using various mouse genetic models. We aim to do the following: (1) briefly discuss the advantages of mouse genetic models and try to resolve inconsistencies, (2) shed light on the technological advantages, pitfalls, and challenges in the development of BM stem cell lineages, and (3) examine the translational relevance of murine models, and utilize existing large human genomic datasets to facilitate data interpretation. Technically, we present this review as a dedicated resource, in which our detailed analyses of the *pros* and *cons* of different mouse strains (in the main text and in [Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}) would enable scientists to efficiently grasp principles of designing mouse genetic models and of choosing appropriate mouse strains of interest. The genomic and molecular analyses, available in [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}, would help researchers to prospectively understand the translational process based on existing genomic databases. Hence, this resource review may be suitable for a broad range of investigators, scientists, biologists, and trainees in different stem cell fields, particularly for scientists working on the hematological and skeletal systems.Figure 1Genomic Organization of the Nestin and Leptin Receptor Genes(A) Nestin and (B) leptin receptor genes in mice, rats, and humans. The graphs were created based on recent data from both the National Center for Biotechnology Information (NCBI) ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov){#intref0030}) and the UCSC Genome Browser ([genome.ucsc.edu](http://genome.ucsc.edu){#intref0035}). The accession numbers for leptin receptor isoforms are: [NM_146146.2](ncbi-n:NM_146146.2){#intref0040} (mouse *Lepr-B* isoform, transcript variant 1, 19 exons), [NM_001122899.1](ncbi-n:NM_001122899.1){#intref0045} (mouse *Lepr-A*, transcript variant 3, 19 exons), [NM_012596.1](ncbi-n:NM_012596.1){#intref0050} (rat *Lepr-B*, 19 exons), and [NM_002303.5](ncbi-n:NM_002303.5){#intref0055} (human *LEPR-B*, transcript variant 1, 20 exons), [NM_001003679.3](ncbi-n:NM_001003679.3){#intref0060} (human *LEPR-A*, transcript variant 3, 20 exons), [NM_001198689.1](ncbi-n:NM_001198689.1){#intref0065} (human *LEPR-A*, transcript variant 6, 19 exons), and [NM_001198687.1](ncbi-n:NM_001198687.1){#intref0070} (human *LEPR-C*, transcript variant 4, 19 exons). Representative leptin receptor isoforms, transcript variant identification numbers, exon numbers, and tissue-specific expression patterns were briefly indicated in the right panel. Of note, the asterisk sign (^∗^) indicates that mouse bone marrow (BM) stromal cells express the *Lepr isoform b* based on the existence of *Lepr*-Cre^+^ cells around sinusoids of the BM ([@bib53]) and the NLS-Cre cassette (in the *Lepr*-Cre transgene), which is inserted into the 3′ of the stop codon at exon 19 of the transcript variant 1 ([@bib15]).E or Ex, exon; ExN, exon numbers; FL, fetal liver; HET, hematopoietic tissues; I, intron; Iso, leptin receptor protein isoform; *Lepr*/*LEPR*, the leptin receptor gene; *Leprot*/*LEPROT*, leptin receptor overlapping transcript; *Nes*/*NES*, the gene coding for nestin; tv, transcript variant; P, promoter.Figure 2DNA Transgene Expression Vectors and Regulatory Mechanisms(A) Transgene expression vectors based on the rat *Nes* gene. Top panel: *Nes*-GFP, subcloned into the pBSM13 vector, contains the 5.8-kb rat *Nes* promoter and the 1.8-kb neural-specific intron-2 enhancer fragment (i2E), which flanked the enhanced version of GFP (EGFP). The 8.7-kb final construct, mimicking the arrangement of the regulatory sequences of the *Nes* or *NES* found in the rat, mice, and humans, was used for the pronuclear injections of the fertilized oocytes ([@bib38]). Lower panel: *Nes*-CreER^T2^ comprises the T2 mutant form of a Cre recombinase-estrogen receptor fusion (Cre-ER^T2^) ([@bib17]) under the control of a thymidine kinase promoter (TKP) driven by the 1.8-kb i2E as described in the top panel ([@bib4]). In *Nes*-GFP transgenic mice, a cell-specific transcriptional complex at the promoter might interact with the neural-specific intron-2 enhancersome, thereby mediating different gene expression patterns in miscellaneous cell types including BM cells. However, in the case of *Nes*-CreER^T2^ mice, the transgene is largely driven by the intron 2 enhancersome.(B) Transgene expression vectors based on the chondroitin sulfate proteoglycan four gene (*Cspg4*), also known as *NG2* (neural/glial gene). (1) Genomic organization of the *Cspg4* gene is based on the recent genomic information from the NCBI sequence ([NM_1390012](ncbi-n:NM_1390012){#intref0075}) with a scale bar (5 kb). (2 and 3) *NG2*-CreBAC ([@bib54]) and *NG2*-CreER™BAC ([@bib55]) DNAs were used for generating *NG2*-Cre and *NG2*-CreER™ transgenic mice, respectively. In brief, a 208-kb mouse bacterial artificial chromosome (BAC) containing the entire *Cspg4* gene was modified by introducing a Cre recombinase cDNA with a nuclear localization signal (NLS) or a CreER™ cDNA ([@bib13], [@bib34]) into exon 1 of the *Cspg4* gene, followed by a rabbit β-globin polyadenylation sequence, poly(A). These two transgenes were microinjected into the pronucleus of fertilized oocytes from C57BL/6J mice to generate the transgenic lines of interest.a, adaptor protein(s); b, basal transcriptional factor(s); Cre-ER^T2^, Cre recombinase fused to the human estrogen receptor ligand-binding domain with a triple mutation (i.e., G400V/M543A/L544A), which does not bind its natural ligand (17β-estradiol); Cre-ER™, Cre recombinase fused to a G525R mutant form of the mouse estrogen receptor ligand-binding domain; cs, cell-specific, Ex, exon; i2E, the intron 2 enhancer fragment of the rat *Nes* gene; P, promoter; Pol II, RNA polymerase II; SV40 pA, the polyadenylation sequences from the simian virus 40; TF, transcriptional factor; TKP, a 160-bp herpes simplex virus (HSV) thymidine kinase (TK) promoter; u, unidentified factor(s).Figure 3Gene Regulation, Data Interpretation, and Integration(A) Regulation of transgene at different molecular levels. Transgene reporter expression may or may not overlap with endogenous gene expression patterns. With regard to a transgene reporter activation, various experimental outcomes may be possible, which need to be confirmed by additional downstream assays (e.g., mRNA and protein expression).(B) A scheme of data integration between mouse transgene reporter data and human epigenomic databases. Data from mouse genetic models may be directly translated and integrated into human BM biology given that they shared highly similar genomic structures and regulatory elements. Existing genomic and epigenomic databases can be also used to facilitate mouse data interpretation and help design humanized mouse models.Figure 4Representative Analysis of the Epigenetic Marker H3K4me1 at the *NES* and *LEPR* Loci(A) Clustering analysis of deposited H3K4me1 ChiP-seq data ([www.genboree.org](http://www.genboree.org){#intref0080}) in 219 samples that comprise cell types from three germ layers and trophectoderm ([Table S2](#mmc2){ref-type="supplementary-material"}, [Figure S1](#mmc1){ref-type="supplementary-material"}). H3K4me1 data for 219 human samples (GEO accession number: GGSM621418) were imported into the Genboree Workbench from Release 9 of the Human Epigenome Atlas ([www.genboree.org](http://www.genboree.org){#intref0085}). Human genome assembly GRCh37/hg19 (February 2009) was used for this analysis. The normalized values for *NES* and *LEPR* were exported for cluster analysis and visualization in R ([www.cran.r-project.org](http://www.cran.r-project.org){#intref0090}) using the heatmap.2 function.(B) The enlarged views of the regions of interest are presented on the right panel. Asterisks indicate the views of truncated dendrograms. Detailed information for these dendrograms is available from [Figure S1](#mmc1){ref-type="supplementary-material"}. Of note, the genomic localization of exon 20 of the *LEPR* gene is currently not available from the Human Epigenome Atlas ([www.genboree.org](http://www.genboree.org){#intref0095}). Hence, the epigenomic data of exon 20 should be interpreted with caution.H1, human embryonic stem cell line H1 (WA01); H3K4me1, monomethylated histone H3 lysine 4; I, intron; *LEPR or L*, the leptin receptor gene; *LEPROT* or *Leprot*, leptin receptor overlapping transcript; "MSC," "mesenchymal stem cells"; *NES or N*, the gene coding for nestin; UTR, untranslated region.Figure 5Deciphering Molecular Cell-Identity Codes through Integration of Data-Informatics Cascades (from Epigenomics, Transcriptomics, and Chromatin Proteomics) into Regulatory Signatures(A) Analysis of the epigenomic markers (H3K27ac, H3K4me1, and H3K4me3 at the *NES* and *LEPR* loci) was based on the Encyclopedia of DNA Elements (ENCODE) at the UCSC ([genome.ucsc.edu](http://genome.ucsc.edu){#intref0100}). Human genome assembly GRCh38/hg38 (December 2013) was used for this analysis. The ChiP-seq data are arranged to correspond precisely to their genomic locations. Five (H1, human skeletal muscle cells and myoblasts \[HSMM\], HUVEC, normal human lung fibroblasts \[NHLF\], and normal human epidermal keratinocytes \[NHEK\]) out of seven cell lines are shown.(B) Mapping of transcriptional regulators on the chromatin at the *LEPR* and/or *LEPROT* loci: *LEPR* (uc001dci.4) is located at chr1:65420652-65641559, based on the orientation of the transcript variant 1 from the RefSeq [NM_002303](ncbi-n:NM_002303){#intref0105}. The enriched transcriptional factors (TFs) on the *LEPR/LEPROT* gene promoter as well as the *LEPR* exon 3 regions are shown. Some of these TFs are color-highlighted based on their role in cellular response and in lineage differentiation.(C) Multiple regulatory models for the *LEPR/LEPROT* locus: the full-length human *LEPR* gene (containing 20 exons) is transcribed from the P1 promoter. In the *Lepr*-IRES-NLS-Cre targeting construct (containing the *neo* gene, flanked by the *FRT* sites) was introduced by homologous recombination immediately after the mouse *Lepr* stop codon at exon 19 (human exon 20 counterpart) ([@bib15]). This *Lepr*-Cre knockin mouse model has been widely used to monitor transcriptional activity of the full-length mouse *Lepr* gene that encodes the Lepr-B protein isoform ([@bib29], [@bib39], [@bib44], [@bib53]).Brg1, SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4); CRC, chromatin-remodeling complexes including histone modifications enzymes; E2F6, E2F transcription factor 6; EGR1, early growth response 1; ELF1, E74-Like factor 1 (Ets domain transcription factor); Ex, exon; EZH2, enhancer of Zeste 2 polycomb repressive complex 2 subunit; GABPA, GA binding protein transcription factor, alpha subunit 60 kDa; GATA2, GATA binding protein 2; GATA3, GATA binding protein 3; H1, H1 (WA01) human embryonic stem cell line; HSMM, human skeletal muscle myoblasts (mesoderm); HUVEC, human umbilical vein endothelial cells (mesoderm) from blood vessels; *LEPROT*, leptin receptor overlapping transcript; NAC: neuronal lineage activator complexes that include either BRG1 or PHF8 or both; NHEK, normal human epidermal keratinocytes (ectoderm); NHLF, normal human lung fibroblasts; NRSF, known as REST (RE1-silencing transcription factor); P1, the promoter of the canonical *LEPR* gene; P2, an alternative promoter at the 5′ of exon 3 of *LEPR*; p300, EP300 (E1A binding protein P300); PHF8, PHD finger protein 8, a histone lysine demethylase that preferentially acts on histones in the monomethyl or dimethyl states; Pol II, RNA polymerase II; RAD21, RAD21 cohesin complex component; SIN3A, SIN3 transcription regulator family member A; STAT3, signal transducer and activator of transcription 3 (acute-phase response factor); SUZ12, SUZ12 polycomb repressive complex 2 subunit; TAF1, TAF1 RNA polymerase II, TATA-box binding protein (TBP)-associated factor, 250 kDa; TBP, TATA-box binding protein; YY1, YY1 transcription factor.Table 1Representative Analyses of Marker Genes Used for Bone Marrow and Skeletal Stem Cell IdentitiesMouse StrainsMajor DescriptionsAuthors\' CommentsReferences*Col2.3-GFP* transgenic miceexpress GFP in osteoblasts and osteocytes under the control of the 2.3-kb rat Col 1a1 (procollagen, type 1, alpha 1) promoteruseful for studying bone development and osteoblast lineage tracing; wary of rat subspecies sequence effects[@bib24]*Cxcl12*-dsRed▸express dsRedE2 from the mouse endogenous *Cxcl12* promoter▸the dsRed knockin produces a strong loss-of-function allele▸dsRed recognized by anti-RFPuseful for identifying Cxcl12-expressing perivascular stromal cells and endothelial cells in the bone marrow[@bib16]*Cxcl12*-GFP\
knockin micehighly enriched in Cxcl12-abundant reticular (CAR) cells within the intra-trabecular space in the bone marrowendothelial cells and the endosteal surface osteoblasts show faint or undetectable GFP signals[@bib2], [@bib49]Gt(ROSA)26Sor^tm1(HBEGF)Awai^▸have the simian diphtheria toxin receptor (*DTR*; from simian Hbegf) inserted into the Gt(ROSA)26S or the ROSA26 locus, whose expression is suppressed by an upstream loxP-flanked STOP sequence▸inducible expression of *DTR* by *Cre* recombinasesuitable for ablation of cells that express DTR following diphtheria toxin treatment[@bib9]*Lepr*^*fl/fl*^B6.129P2-Lepr^tm1Rck/J^, also known as: ObR^Flox^▸have loxP sites on either side of exon 1 of the mouse *Lepr* gene▸delete exon 1 when bred to a Cre recombinase-expressing mice under a tissue-specific promoter▸useful in studies of obesity and *Lepr* related cell lineage analysis▸beware of expression of short *Lepr* isoforms that are initiated after exon 1[@bib11]\
<http://www.jax.org/>*Lepr*-CreL B6.129-Lepr^tm2(Cre)Rck/J^ (*Lepr*-Cre); the targeting vector contains an IRES-NLS-*Cre* and a *neo* (flanked by frt sites) inserted immediately 3′ of the stop codon in the last exon of the *Lepr* genetranscripts may terminate in many *Lepr* transcript variants that do not contain the last exon of the canonical Lepr isoform (Lepr-B)[@bib15]*Mx-1*-Cre,\
transgenic miceB6.Cg-Tg(*Mx1*-cre)1Cgn/J, also known as *Mx*-Cre and *Mx1*-Cre (BALB/c): the *Mx-1*-Cre transgene contains Cre recombinase under the control of the *Mx-1* promoter that is silent in healthy mice▸the *Mx-1* promoter is highly sensitive to interferon α/β and synthetic double-stranded RNAs, e.g., poly(I:C)▸cautions should be taken when experimental conditions involving interferons and exogenous double-stranded RNAs[@bib27]\
<http://www.jax.org/>*Nes*-CreCre recombinase is expressed under the control of the 5.8-kb rat *Nes* promoter and the 1.8-kb intron 2 enhancer element▸no ER^T2^ fragment in the construct▸genomic orientation of the *Nes* genomic elements is similar to that of *Nes*-GFP described by [@bib38][@bib51]*Nes-*CreER^T2^\
transgenic miceC57BL/6-Tg(Nes-cre/ER^T2^)KEisc/J:▸express the T2 mutant form of a Cre-estrogen receptor fusion (Cre-ER^T2^) under the control of the 1.8-kb rat *Nes* intron-2 enhancer (i2E) element and a 160-bp HSV TK promoter followed by an SV40 polyA site▸Cre-ER^T2^ fusion protein activity: inducible to the nucleus at high levels following binding of tamoxifen, which deletes the floxed sequences in cells of bred mice▸the *Nes*-CreER^T2^ transgene directs *Cre* expression in *Nes*-expressing cells in the subventricular zone (SVZ) and subgranular zone (SGZ)▸useful for studying the lineage commitments in both adult and developing mouse brains▸the 4.2-kb transgene fragment excluded the majority of the rat 5′ promoter sequence▸the intron-2 enhancer element orientated differently from that of the *Nes*-GFP construct ([@bib38]); thus may have differential transcriptional effects▸a complicated inducible system, involving mixed estrogen-agonist effects of tamoxifen on the impairment of bone growth, apoptosis in growth plate chondrocytes in cultured rat metatarsal bones, and signal transductions between endothelial cells and pericytes[@bib4], [@bib10], [@bib17], [@bib25], [@bib30], [@bib56]*Nes*-GFPTg(Nes-EGFP)33Enik: a *Nes*-GFP reporter in transgenic mice, driven by the 5.8 promoter and 1.8-kb intron 2 enhancer of the rat *Nes* gene▸predicting CNS neural stem cell or progenitor specific promoter and intron 2 enhancer transcriptional activity▸rat sequence in a mouse model▸expected differences among *Nes*-GFP, *Nes*-Cre, and *Nes*-CreER^T2^ strains[@bib32], [@bib38], [@bib56]*NG2*-CreER™B6.Cg-Tg(Cspg4-Cre/Esr1^∗^)BAkik/J,▸*NG2*-CreER™ BAC transgenic mice▸tamoxifen-inducible Cre (CreER™) under the control of the mouse *NG2* (*Cspg4*) promoter/enhanceruseful for inducible Cre recombinase expression in NG2-expressing glia and other cell types[@bib55]; <http://www.jax.org/>*P0*-Cretransgenic mice expressing Cre recombinase directed by the myelin protein zero (*P0*) gene promotergenetic tools for labeling neural crest cell lineages such as Schwann cells[@bib18], [@bib52]*Prx1*-CreB6.Cg-Tg(Prrx1-cre)1Cjt/J: expresses *Cre* under the control of a *Prrx1-*derived enhanceruseful for studying limb bud development and patterning[@bib35]*Wnt1*-Cre▸carrying Cre cDNA between *Wnt1* promoter and enhancer▸widely used in the study of brain development, the neural crest and its derivatives▸phenotypes can be complicated by ectopic activation of canonical Wnt/β-catenin signaling related to increased Wnt1 protein expression▸may be used as a gain-of-function model for studying Wnt signaling mechanisms in middle brain development[@bib14], [@bib33]*Wnt1*-Cre2Cre expression under the control by 1.3-kb 5′ promoter and 5.5-kb 3′ enhancer▸serve similar purposes to the original *Wnt1*-Cre ([@bib14])▸deprived of complicated phenotypes associated with gain of function of Wnt1[@bib33][^1]

Mouse Genetic Models: Advantages and Problems Solved {#sec1.2}
----------------------------------------------------

Mouse genetic models have dramatically advanced our understanding of many fundamental developmental processes in both the skeletal and hematological systems, thereby accelerating the processes of translational medicine ([@bib7], [@bib20], [@bib42]). These mouse models offer cell lineage mapping *in vivo*, a powerful approach to study specific cell types, numbers, physiological and pathological states, and particularly cell signaling pathways in stem cell niches ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}).

Stem cell niches can be briefly defined as a specific microenvironment that contains and sustains stem cells in an undifferentiated state. The basic components of a BM stem cell niche comprise BM stroma, extracellular matrices, HSCs, SCCs, Cxcl12-abundant reticular (CAR) cells, adipocytes, endothelial cells, and different types of stromal cells not fully defined to date. These niche-supporting cells secrete specific niche factors encoded by many HSC niche maintenance genes (such as *Cxcl12*, *KitL*, *Angpt1*, and *Lepr*) at restricted regions and mediate many intercellular interactions ([@bib23]). Several known niche-supporting cells include CAR cells ([@bib49]), *NG2*^+^/*Nes*-GFP^high^ cells ([@bib29]), and *Lepr*-Cre^+^/*Nes*-GFP^low^ cells ([@bib53]). Technically, niche-associated gene promoter or enhancer activity as well as mRNA expression can be monitored and targeted by different fluorescent reporter proteins such as GFP. Thus far, mouse genetic models combined with imaging analysis have been the most widely used tool to successfully answer long-standing questions in developmental biology, which include the origins, identities, and locations of postnatal SSCs and HSCs. It is clear now that the major source of SCCs in human BM is tightly associated with CD146^+^/CD45^−^/Ter119^−^ reticular pericytes ([@bib46]) and *Lepr*-Cre^+^/*Nes*-GFP^low^ cells near perisinusoids ([@bib53]) in mice. The major HSC niche has also been confidently localized at BM perivascular regions containing specific types of stromal cells ([@bib1], [@bib29]).

[Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"} summarize a significant amount of data, with point-to-point interpretations and comments of each reporter mouse strain, related to BM cell lineage development, perivascular stromal cells, and neural crest cells. However, to better understand the *pros* and *cons* of genetically modified strains, we comprehensively analyzed two frequently used transgenes (i.e., *Nes* and *Lepr*) at different developmental stages ([Table S1](#mmc1){ref-type="supplementary-material"}; [Figure 1](#fig1){ref-type="fig"}). These two individual genes are chosen, not only for their frequent use in BM niche studies, but also for their transcriptional activities that have empowered us to mark several important niche-supportive cell populations (i.e., *Nes*-GFP^high^, *Nes*-GFP^low^, and *Lepr*-Cre^+^ BM stromal cells) ([@bib29], [@bib53]). Accordingly, there is an increasing body of data generated from using these mouse models ([Table S1](#mmc1){ref-type="supplementary-material"}). For example, combined with other transgene reporters such as *NG2*-CreER™, a tamoxifen-inducible Cre recombinase-estrogen fusion protein driven by the *NG2* promoter-enhancer, scientists were able to identify two important BM cell populations. These two distinct cell populations; i.e., *NG2*-CreER^TM+^/*Nes*-GFP^high^ and *Lepr*-Cre^+^/*Nes*-GFP^low^ cells, likely constitute a distinct HSC niche at the periarteriolar and a major SSC source at the perisinusoidal regions ([@bib29], [@bib53]). The existence of distinct HSC niches, presumably with different functions, is currently an important topic under debate ([@bib1], [@bib3], [@bib29], [@bib43]). Despite the enthusiasm of applying transgene-based models for *in vivo* cell-fate mapping, there are emerging controversial concepts, inconsistent data, and inappropriate data interpretation due to the limitations of mouse genetic systems.

Mouse Genetic Models: Disadvantages, Pitfalls, and Experimental Discrepancies {#sec1.3}
-----------------------------------------------------------------------------

Noticeably, there are numerous limitations of mouse genetic models, which can be introduced by the experimental design of generating genetically engineered mice, to experimental data collection and interpretation. In general, the causes of experimental variability could be classified into the following four major categories, which include the following: (1) the designs of transgenes or targeting vectors used for generating transgenic mice; (2) random chromosomal integrations of genetically identical transgenes or similar transgenes; (3) methods of gene expression (e.g., constitutive versus inducible gene expression systems) and associated cellular cytotoxicity; and (4) complicated dynamic changes of cellular and molecular states of cells in BM throughout development. In the following sections, we will use some representative examples to highlight the above-mentioned major causes of experimental variability and discrepancies.

### Mouse Genetic Model Designs: Genomic Elements, Orientations, and Gene Reporter Data Interpretation {#sec1.3.1}

It is worth noting that the choice of promoter sequences and enhancer elements in a reporter construct might have a major impact on reporter activity in mouse models. As far as *Nes-*GFP and *Nes*-CreER^T2^ mouse models are concerned, both transgenes certainly report transcriptional activation of the *Nes* gene. However, their transcriptional activities are apparently controlled by two different genetic systems ([Figure 2](#fig2){ref-type="fig"}A). *Nes*-GFP expression is driven essentially by the 5′ 5.8-kb promoter and the 1.8-kb intron 2 enhancer (i2E) ([Table S1](#mmc1){ref-type="supplementary-material"}; [Figure 2](#fig2){ref-type="fig"}A). However, in *Nes*-CreER^T2^ transgenic mice, a tamoxifen-inducible Cre-estrogen fusion cassette (i.e., CreER^T2^) is driven by a thymidine kinase promoter under the control of the 5′ i2E element ([Figure 2](#fig2){ref-type="fig"}A). Thus, the 4.2-kb transgene fragment excludes the majority of the rat 5′ *Nes* promoter sequence, which has a different genomic orientation from that of the *Nes*-GFP construct ([@bib38]).

Not surprisingly, some experimental discrepancies have been observed from these two genetically different transgenes. *Nes*-CreER^T2+^ and *Nes*-GFP^+^ cells were not co-localized, but differentially presented at the prenatal stage in BM ([Table S1](#mmc1){ref-type="supplementary-material"}). *Nes*-CreER^T2+^ cells are likely involved in fetal bone development based on their locations near the osteochondral junction and trabecular bone at the prenatal stage, but not in committing to neonatal and postnatal bone development ([@bib23]). It appears that *Nes*-CreER^T2+^ cells co-localize with *Nes*-GFP^+^ pericytes at the neonatal stage (i.e., P0 to P14) ([@bib23]). Seemingly, *Nes*-GFP^+^ stromal cells did not contribute to fetal endochondrogenesis ([@bib23]), but subsequently initiated their role in specifying osteoblasts at the neonatal stage (i.e., P0 to P10) ([@bib44]). Consistently, a *Lepr*-Cre^+^/*Nes*-GFP^low/+^ cell population, without *Nes*-CreER^T2^ expression, was shown to be a major SSC source in the mouse BM at a postnatal stage ([@bib53]). Thus, *Nes*-CreER^T2+^ and *Nes*-GFP^+^ cells have distinct functions in specifying SSC lineage development in BM. Still, the underlying molecular basis for the above discrepancies between *Nes-*GFP and *Nes*-CreER^T2^ mouse strains remains to be elucidated ([@bib23], [@bib44]).

We speculate that the above discrepancies could be partially explained by the different orientation of their genomic and vector elements ([Figure 2](#fig2){ref-type="fig"}A). The *Nes*-CreER^T2^ transgene, containing the i2E, likely functions as a weaker reporter of neuronal enhancer complexes (due to its orientation). *Nes*-GFP, containing the *Nes* promoter and i2E and mimicking the orientation of the endogenous *Nes* gene, reports a wide-range of transcriptional activities, ranging from weak to strong GFP signals, at different developmental stages ([Figure 2](#fig2){ref-type="fig"}A). Likewise, there are two transcriptional activities that regulate *Nes*-GFP, which are differentially associated with specification of the SSC lineage (defined by *Lepr*-Cre^+^/*Nes*-GFP^low/+^) and with the periarteriolar HSC niche (defined by *NG2-CreER*^*TM+*^/*Nes*-GFP^high^ cells).

In the case of *Lepr* regulation, one potential misinterpretation of transcriptomic data might also be due to the orientation of reporter genes (e.g., GFP) that are used to depict transcriptional activity of different transcript variants. The *Lepr* has a large and complicated genomic organization, which transcribes multiple mRNA variants from a promoter (designated as P2), which is different from that of humans (P1) ([Figure 1](#fig1){ref-type="fig"}B). Interestingly, the mouse P2 promoter-initiated transcripts are often terminated at different exons that are proximal to mouse exon 19 (exon 20 in the human counterpart) of the canonical *Lepr gene* ([Figure 1](#fig1){ref-type="fig"}B). Therefore, a knockin reporter immediately after exon 19 in mice only depicts the canonical *Lepr* transcriptional activities ([@bib15]), likely masking or underscoring the contribution of different *Lepr* isoforms or alternative transcripts (terminated at a different exon) to lineage differentiation ([@bib29], [@bib53]). In general, *Nes*- or *Lepr*-driven transgene or knockin gene expression seems far more complicated than their endogenous mRNA and protein expression at different developmental stages ([Table S1](#mmc1){ref-type="supplementary-material"}). Therefore, genomic elements and their orientations must be taken into consideration when designing or choosing desired genetic models, and interpretation of transgene reporter data.

### Random Chromosomal Integration of Transgenes {#sec1.3.2}

Besides the interference from genomic elements and their orientations, random chromosomal integrations of the same transgene could be another major factor that explains different transgene expression patterns in mouse BM. Theoretically, no two transgenic lines are created equal when the genomic elements are randomly integrated in the mouse genome. The variability of transgenic lines has created some confusion and misinterpretation of data when using transgenic reporter as markers. In the case of the *Nes* gene, there are approximately nine *Nes*-CreER^T2^ transgenic lines that have been designed and used to study mouse neural stem cells and progenitors ([@bib50]). However, the expression patterns of these *Nes*-CreER^T2^ lines vary greatly in the mouse brain, apparently because of random chromosomal integration. Only very small subset lines expressed *Nes*-CreER at the neurogenic zones of the adult brain, like that of the endogenous *Nes* gene ([@bib50]). Thus, each individual line should be fully characterized prior to use for a specific need.

### Gene Expression Methods: Constitutive Versus Inducible Expression {#sec1.3.3}

It is conceivable that different gene manipulations would also have a significant impact on their expression patterns. As already discussed above, *Nes*-GFP and *Nes*-CreER^T2^ have different transgene expression patterns in the BM ([@bib23], [@bib44], [@bib53]), which may be partially explained by their differences in regulatory elements and their orientations in the expression vectors ([Figure 2](#fig2){ref-type="fig"}A). Moreover, these two transgenes also differ in the regulatory elements that control their expression. *Nes*-GFP has a constitutively active *Nes* promoter and i2E in neurogenic cells ([Figure 2](#fig2){ref-type="fig"}A). *Nes*-CreER^T2^ contains a tamoxifen-inducible CreER^T2^. Nevertheless, the definite role of CreER^T2^ in the contribution to experimental discrepancies remains to be determined for the complexity of the two transgene systems. Moreover, it also remains to be established whether a constitutive versus inducible modification would lead to a significant experimental difference or discrepancy.

Fortunately, a pairwise comparison between another two transgene expression systems (i.e., *NG2*-Cre and *NG2*-CreER™), in which the genetic elements (i.e., the nuclear localization signal \[NLS\] and CreER™) that control constitutive and inducible expression, respectively, are the only difference ([Figure 2](#fig2){ref-type="fig"}B). This comparison presents a convincingly positive answer to the above question ([@bib3]). *NG2*-Cre, with a constitutively active NLS, marks BM stromal cells at both periarteriolar and sinusoidal areas; whereas *NG2*-CreER™, with a tamoxifen-inducible Cre-ER™, preferentially marks periarteriolar cells, presumably presenting distinct HSC niche-supporting function ([@bib3]). Thus, *NG2*-Cre- and *NG2*-creER™-marked cells showed differential HSC niche-supporting functions, in which *NG2*-Cre^+^, but not *NG2*-creER^TM+^, cells are the source of the major HSC niche factor, Scf, whose deletion in *NG2*-Cre mice led to a defect in multi-lineage reconstitution in the BM ([@bib3]). Clearly, these results provide insights into how different genetic approaches can impact on experimental conclusions, thereby presenting, at least partial resolution, of the current debate between the existence of distinct and uniform HSC niches in BM ([@bib1], [@bib29]).

Despite the inducible systems that enable a spatial-temporal activation of marker genes for single-cell lineage tracing, some gene-inducible systems are particularly leaky in terms of their system specificity. Moreover, the side effects of inducible reagents on a particular cell type should be taken into account. This could be exemplified by the intriguing ligand-dependent Cre recombinase that is inducible by administration of tamoxifen. Tamoxifen blocks the actions of estrogen, a female hormone, and is used to treat several types of breast cancer in clinics. It has been shown that tamoxifen has mixed estrogen-agonist effects and may alter bone and chondrocyte growth, and signal transduction between endothelial cells and pericytes ([Table 1](#tbl1){ref-type="table"}) ([@bib10], [@bib25]). Furthermore, cellular cytotoxicity may be encountered in both constitutive and inducible systems. Such cytotoxicity has been observed in Cre-ER activation in induced hematological disorders ([@bib22]), thus rendering non-specific phenotypes to BM stromal cells.

It was also shown that high levels of Cre recombinase expression in mouse embryo fibroblasts induced DNA damage and inhibited cell growth in a Cre-ER activity-dependent manner ([@bib36]), and, in neuronal stem and progenitor cells, led to increased aneuploidy, cell death, and brain developmental defects ([@bib19]). These studies highlight the potential problems for developmental studies of BM cells, especially *Nes*-CreER^T2^- and *NG2*-CreER™-expressing cells with a high neurogenic promoter or enhancer activity. Consequently, it is unknown whether there are significant amounts of *NG2*-CreER^high^ and *Nes*-CreER^high^ cells in previous studies ([@bib1], [@bib29]), which may be eliminated due to a high nuclear Cre activity. Hence, it is important to titrate Cre activity in each individual transgenic line, to use low levels of Cre-ER that permit for desired recombination without cell cytotoxicity, and to have tight tamoxifen-inducible controls when these Cre-based systems are used to study complicated dynamic changes of SSC and HSC niches.

### Complexity of Dynamic Changes of Cellular and Molecular States in Development {#sec1.3.4}

Currently, the big challenge is to deeply understand the complexities of cellular and molecular states of BM cells at different developmental stages, which are thought to be tightly co-regulated by largely unknown mechanisms. At the cellular level, some cell identities present only in a transient state at a specific stage, which sometimes are too dynamic to be identified. For example, we have discussed that *Nes*-GFP^+^ and *Nes*-CreER^T2+^ cells are differentially presented in both prenatal and postnatal BMs. *Nes*-CreER^T2^ transcription may be repressed before the formation of the primary ossification center, but de-repressed after the development of the primary ossification center and the marrow cavity ([@bib44]). Under the condition of tamoxifen induction at P0 and chase to P7, [@bib23] found that *Nes*-CreER^T2+^ cells were highly co-localized with *Nes*-GFP^+^ cells in BM. These data suggest that the *Nes* i2E expression is dominant at the neonatal stage (i.e., P0 to P7), which might have coupled with one core transcriptional mechanism that regulates BM stem cell niches in a developmental stage-specific manner. Of note, promoter/enhancer activity, mRNA expression, and protein expression of the marker gene of interest may be consistent or inconsistent at different developmental stages ([Table S1](#mmc1){ref-type="supplementary-material"}). Thus, specific developmental windows used for induction experiments and retrieving data are required to be consistent or specifically identified for comparative studies.

Regardless of the existence of complicated cell types in BM, the underlying mechanisms that regulate their cell identities involve gene regulation not only at the transcriptional level, but also at many different molecular levels (e.g., epigenomic, post-transcriptional, and translational modifications) ([Figure 3](#fig3){ref-type="fig"}A). These complicated gene regulatory mechanisms might make transgenic data interpretation even more difficult. Therefore, we should be aware that reporter gene expression is not always consistent with its mRNA and protein expression patterns ([Figure 3](#fig3){ref-type="fig"}A). One could not assume that *Nes*-GFP^high^ cells must have high levels of endogenous *Nes* mRNAs or nestin protein expression. In general, each individual mouse strain (e.g., *Nes*-GFP or *Nes*-CreER^T2^) should be considered as an independent assay tool for *in vivo* cell fate, functional analysis, and translational studies of mouse BM biology. In the following sections, we will further discuss the translational implication, potential challenges, and future considerations of mouse genetic models, mainly based on integrating existing genetic data and genomic informatics from both mouse and human studies ([Figure 3](#fig3){ref-type="fig"}B).

### Mouse Genetic Models versus Human Resource Databases: Translational Relevance, Challenges, and Prospective Considerations {#sec1.3.5}

In the biomedical field, the ultimate goals of using diverse animal models are to provide translatable biomedical information to understand the etiology of human diseases and to derive effective clinical treatments for patients. On the one hand, the success of this translational approach relies on the understanding of the interplay of datasets between murine models and the human cells. On the other hand, the availability of genome-wide datasets in the post human genome era offers the possibility to optimize mouse genetic models through existing coherent human datasets ([@bib8], [@bib28]) ([Figure 3](#fig3){ref-type="fig"}B). However, the above interplay approaches have not been well integrated to guide stem cell research. Here, we will focus on the interpretation of mouse model data based on the transcriptomic complexity of marker gene transcripts in both humans and mice. Furthermore, we will shed light on how "generic" epigenomic markers from redundant human epigenomic databases could provide prospective molecular cell identities for facilitating translational biology.

### Transcriptomic Complexity of Marker Gene Transcripts {#sec1.3.6}

To better integrate human genomic data with mouse models, we initially analyzed the genomic organization of the human *NES* and *LEPR* loci, due to the availability of datasets, and because the two reporters, *Nes*-GFP and *Lepr-*Cre, have been extensively used to categorize stem cell identities in animal models as discussed above ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}). [Figure 1](#fig1){ref-type="fig"}A illustrates the genomic organization of these two genes from mice, rats, and humans. In the case of the homolog genes that encode the nestin protein, there are significantly conserved intronic and exonic structures, but with some variations found in the 20- to 25-kb 5′ genomic regions ([Figure 1](#fig1){ref-type="fig"}A). Likely, the similar genomic organizations of *Nes* and *NES* among mice, rats, and humans would make *in vivo* animal studies more relevant to clinical sittings.

However, with respect to the leptin receptor genes, genomic sequence data reveal significant differences between the species in terms of gene structures, function, transcription start sites, alternative transcripts, and the locations of the last exon in each individual transcript ([Figure 1](#fig1){ref-type="fig"}B). During embryonic development, *LEPR* isoform *A* (*LEPR-A*) is expressed in fetal liver, hematopoietic tissues, and the choroid plexus. In adults, *LEPR-A* is highly expressed in mesoendoderm-derived tissues (such as heart, liver, small intestine, prostate, and ovary) ([www.SWISS_Prot](http://www.SWISS_Prot){#intref0010}). However, *LEPR-B* (the canonical isoform) is highly expressed in neuroectodermal tissues, including the choroid plexus and hypothalamus, in adult humans and mice ([Figure 1](#fig1){ref-type="fig"}B). Notably, in humans, there are at least five LEPR protein isoforms derived from six mRNA transcripts, which are expressed in a tissue-specific manner ([Figure 1](#fig1){ref-type="fig"}B). Thus, this genomic or proteomic information is particularly useful for us to design GFP- or Cre-based *Lepr* constructs in murine models to study tissue-specific regulation of cellular states.

Furthermore, the *LEPR* and *LEPROT* (leptin receptor overlapping transcripts) genes, which encode two distinct proteins, share the same promoter and the first two exons ([Figure 1](#fig1){ref-type="fig"}B). The orientation of the two genes are similar in both human and rat genomes, but different from that of mice ([Figure 1](#fig1){ref-type="fig"}B). The mouse *Leprot* is approximately 50 kb away from *Lepr* ([Figure 1](#fig1){ref-type="fig"}B). Importantly, we need to determine where the reporter activity is initiated. The differential activation of *LEPR* and *LEPROT* promoters or enhancers may render opposite interpretations of the results.

### Generic Epigenomic Markers and Molecular Cell Identities {#sec1.3.7}

Redundant epigenomic databases represent a valuable tool for defining various epigenomic and transcriptional states during development. It is unknown whether we could also accurately define molecular cell identities using a panel of "generic" epigenomic markers, which are currently available in miscellaneous human epigenomic databases. We evaluated the presence or absence of the monomethylated histone H3 lysine four epigenomic marker (H3K4me1), at the human *NES* and *LEPR* loci, enabled by the availability of a large H3K4me1 chromatin immunoprecipitation sequencing (ChiP-seq) dataset in 219 human cell samples ([www.genboree.org](http://www.genboree.org){#intref0015}). The 219 samples comprise cell types from all three germ layers and the trophectoderm ([Table S2](#mmc2){ref-type="supplementary-material"}; [Figure S1](#mmc1){ref-type="supplementary-material"}). H3K4me1 usually pre-marks the enhancers that are not active, but primed for activation, in the absence of external stimuli or signals ([@bib48]). As shown in [Figure 4](#fig4){ref-type="fig"}, the dendrogram reveals two genomic clusters that separate the majority of marked introns and exons of *LEPR* from those of *NES* ([Figures 4](#fig4){ref-type="fig"}A and 4B). Moreover, H3K4me1 segregates the previously well-characterized regulatory regions (i.e., intron 1 and 2 enhancers, denoted as i1E and i2E, respectively) of the *NES* (or *Nes*) gene, validating the reliability of using H3K4me1 for cell-identity classification in this analysis. Therefore, H3K4me1 segregates all samples into three major cell clusters, in which cell clusters 1 and 3 are clearly different ([Figures 4](#fig4){ref-type="fig"}A and 4B). Cell cluster 1 (containing predominantly mesodermal derivatives) is apparently regulated by H3K4me1 on the promoter region, intron 1, and exon 2 of the *LEPR* gene ([Figure 4](#fig4){ref-type="fig"}B, lower panel). Interestingly, H3K4me1 marks cell cluster 3, containing predominantly neural and epidermal/ectodermal derivatives (e.g., brain and foreskin tissues), on introns 1 and 2 of the *NES* promoter ([Figure 4](#fig4){ref-type="fig"}B, upper panel). The inclusion of pluripotent stem cells and their differentiated cell types in the cell cluster 3 merely reflects the developmental proximity between the neuroectoderm and embryonic epiblasts. Cell cluster 2, which partially overlaps with the cell clusters 1 and 3, requires additional markers to identify their cell identities. Nevertheless, these data suggest that even a generic marker (such as H3K4me1) on limited genomic loci (e.g., *LEPR* and *NES*) could bear remarkable epigenetic information to classify mesodermal and ectodermal disparities.

Accordingly, we further analyzed three major epigenomic markers, H3K27ac, H3K4me1, and H3K4me3, at the *NES* and *LEPR* loci, based on the Encyclopedia of DNA Elements at UCSC (2003--2012) ([genome.ucsc.edu](https://genome.ucsc.edu){#intref0020}). Unlike H3K4me1, H3K27ac marks active enhancers at transcriptional factor-accessible genomic loci ([@bib12]), whereas H3K4me3 marks gene promoters that are active or poised to be active ([@bib5], [@bib31]). In brief, we were able to integrate data-informatics cascades from epigenomics, transcriptomics, and chromatin proteomics into regulatory complexes for monitoring cell identity in human embryonic stem cell line H1 (WA01) and other mesodermal or ectodermal cell lines (i.e., human skeletal muscle cells and myoblasts, HUVECs \[human umbilical vein endothelial cells\], normal human lung fibroblasts, and normal human epidermal keratinocytes) ([Figure 5](#fig5){ref-type="fig"}A). Mapping of potential transcriptional regulators on chromatin at the *NES* and *LEPR* loci (e.g., at BM stromal cell cluster 1, [Figure 4](#fig4){ref-type="fig"}B) would provide new insights into *Nes*-GFP and *Lepr*-Cre transcriptome activities that are commonly monitored in mouse models.

Indeed*, LEPR* represents a complicated regulation due to the presence of multiple alternative transcripts and the co-regulated *LEPROT* gene ([Figure 1](#fig1){ref-type="fig"}B). The three histone markers are increased on the promoter region adjacent to exons 1 and 2 among the four cell lines (except H1) ([Figure 5](#fig5){ref-type="fig"}A, right panel). Interestingly, H3K4me1 was located at multiple regions in intron 2 and in two 3′ exonic areas in HUVECs ([Figure 5](#fig5){ref-type="fig"}A, right panel). The biological consequences of these sites remain unclear. However, they might be associated with alternative transcription start sites of the gene, therefore potentially interfering with *Lepr*-Cre transcriptome interpretation in endothelial cells. Based on the recruitment of RNA polymerase II, we identified at least two promoters (i.e., P1 and P2) on the full-length *LEPR.* The two promoters appear to be consistent with their epigenetic states ([Figures 5](#fig5){ref-type="fig"}A, right panel, 5B, and 5C). These data confirm the presence of alternative transcripts due to differential initiation of transcription under diverse cellular contexts.

Interestingly, a neuronal repressor complex (that involves both NRSF and SIN3A) was drastically downregulated at the P1 promoter. Concomitantly, there is an increase in neural activation complex (NAC) that contains PFH8, GABPA, and ELF1 at the both P1 and P2 promoters ([Figures 5](#fig5){ref-type="fig"}B and 5C). The P2 promoter (located at the 5′ end of exon 3) seems to be a weaker promoter compared with P1. Moreover, P2 is apparently regulated by the NAC that includes either BRG1 or PHF8 (or both), polycomb group repressive complex proteins (e.g., EZH2 and SUZ12), and GATA binding proteins (e.g., GATA2 and GATA3) ([Figure 5](#fig5){ref-type="fig"}B). Thus, a neural-specific regulation of the P2 promoter has been implicated in the human *LEPR* gene ([@bib47]).

Taken together, transcription factor profiling of the *LEPR* promoters reveals a potential molecular switch between neuroectodermal and mesodermal regulation, suggesting a possible coupling mechanism between sequential de-repression and activation, which controls cell-type-specific transcriptional activity at the P1 and P2 promoters ([Figure 5](#fig5){ref-type="fig"}C). Of note, we need to be aware of using eipgenomic data from human cell lines, which might increase the possibility of altered epigenetic marker expression under certain cell culture conditions. In the future, these analyses should include large-scale epigenomic data from human tissues and purified human cell populations. It would be also desirable to have a side-by-side comparative analysis between mouse and human epigenomic datasets. Ultimately, we would be able to make humanized mouse models by integrating partial human genomic or epigenomic information into a transgenic mouse model for translational studies.

Concluding Remarks {#sec1.4}
------------------

Constitutive and inducible expression based on various types of transgenes have identified a plethora of functionally important stem cell and progenitor populations in BM. Various experimental discrepancies, data irreproducibility, and misinterpretations could be explained, minimized, and circumvented if we have a better understanding of these mouse genetic systems. Ideally, we should develop and apply non-toxic, cell-type-specific, regulatable, and humanized mouse genetic systems, combined with other technological approaches for *in vivo* cell-fate analysis. Theoretically, molecular signatures of cell identities could be evident at multiple levels of gene regulation, resulting in activation of transcriptional complexes, mRNA transcription, and protein translation at different developmental stages. Practically, we need to be aware of these differences when we interpret data based on mouse reporter activity (e.g., from *Nes*-GFP, *Nes*-CreER, and *Lepr*-Cre), mRNA transcripts, and protein expression. Each gene regulation or expression mechanism should be considered as an independent assay for lineage analysis. Importantly, all genetic and epigenetic assays should be combined with definitive surface marker analysis and genome-wide "clusterome" to accurately define specific cellular states and cell identities. Precise understanding of the regulation of reporter transcriptomes in murine models would enable us to accurately decipher diverse cell fates in the BM.
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[^1]: Cre, Cre recombinase; Cxcl12, chemokine (C-X-C motif) ligand 12; GFP, green fluorescent protein; HSV, herpes simplex virus; IRES, internal ribosome entry site; Neo, neomycin resistance gene; NLS, nuclear localization signal; RFP, red fluorescent protein; TK, thymidine kinase.
